TG Therapeutics Raises 2024 Revenue Guidance Amid Soaring BRIUMVI Sales
TG Therapeutics' Q2 2024 results show BRIUMVI sales at $72.6M, prompting a revenue guidance raise to $290-$300M.
- Latest
- Trending
TG Therapeutics' Q2 2024 results show BRIUMVI sales at $72.6M, prompting a revenue guidance raise to $290-$300M.
Amgen's Q2 profit drops due to higher expenses, but revenue sees a 20% increase, driven by Horizon acquisition.
Ubisoft unveils 'Captain Laserhawk' on Ethereum Layer-2 Arbitrum—a community-driven, transmedia game inspired by Netflix’s "Blood Dragon Remix."
Thoma Bravo seeks $2 billion valuation for ESG software maker Cority, engages Goldman Sachs for potential sale process.
MoonTaurus (MNTR) predicted to surge 1400% by 2024, surpassing Shiba Inu and Dogecoin. Early presale frenzy drives massive investor interest.
"Dogecoin and Pepe tumble amid massive liquidations, while AI-integrated meme coin Raboo ($RABT) gains momentum with innovative features."
"Semler Scientific Q2 2024: Strong operations despite 22% revenue dip, spotlight on Bitcoin investment as inflation hedge and strategic growth ...
Castle Biosciences reports 74% Q2 revenue surge to $87M, driven by test usage and price hikes, with net income rebounding ...
Clover Health reports its first-ever positive net income in Q2 2024, driven by financial growth and a technology-driven care platform.
"SEC Chair Gary Gensler signals smooth path toward approval of Spot Ethereum ETFs, stressing compliance and transparency. Launch expected by ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.